|
PR1 leukemia peptide vaccine
|
DB15276 |
[PR1 leukemia peptide vaccine is under investigation in clinical trial NCT00513578 (Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome).] |
|
GDC-0077
|
DB15275 |
[GDC-0077 is under investigation in clinical trial NCT03006172 (To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer).] |
|
Efgartigimod alfa
|
DB15270 |
[Efgartigimod alfa is under investigation in clinical trial NCT03669588 (An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness).] |
|
Edratide
|
DB15272 |
[Edratide is under investigation in clinical trial NCT00203151 (A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus).] |
|
Crizanlizumab
|
DB15271 |
[Crizanlizumab is a humanized IgG2 monoclonal antibody used to reduce the frequency of vaso-occlusive crises in patients with sickle cell disease.[L10097] Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa, and certain parts of India. The genetic mutation associated with this disease leads to the formation of abnormal, sickle shaped red blood cells that aggregate and block blood vessels throughout the body, causing vaso-occlusive crises. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications arising from the blockage of blood vessels.[T734]
Currently, patients are prescribed [hydroxyurea] to raise levels of fetal hemoglobin as a method of reducing morbidity and mortality.[A187904] Though hydroxyurea has been shown to reduce the frequency of vaso-occlusive crises, adherence to this therapy is difficult due to adverse effects and the high variability of response to the drug between patients.[A187907] Crizanlizumab, or SEG101, is given once every 4 weeks and may improve patient adherence. It was developed by Novartis and was granted FDA approval on November 15, 2019.[L10097]] |
|
Phenylphosphate
|
DB03298 |
|
|
N-Succinyl Phenylglycine
|
DB03299 |
|
|
alpha-Conotoxin VC 1.1
|
DB05724 |
|
|
ALKS 29
|
DB05723 |
[ALKS 29 is a new product candidate for the treatment of alcohol dependence. It is being developed by Alkermes, Inc.] |
|
CGC-11047
|
DB05722 |
[CGC-11047 is a polyamine analog designed to halt cell growth and induce apoptosis.] |
|
EVT 201
|
DB05721 |
[EVT 201 is a novel partial positive allosteric modulator of the GABAA receptor complex which is being developed as a treatment for insomnia. It is being developed by Evotec Inc.] |
|
Ncs-Chromophore
|
DB04408 |
|
|
Naphthalene Trisulfonate
|
DB04409 |
|
|
CYT006-AngQb
|
DB05739 |
[CYT006-AngQb is a therapeutic vaccine in development for treatment of hypertension. It is designed to instruct the patient’s immune system to produce an antibody response against angiotensin II, a small peptide that causes blood vessels to narrow and results in increased blood pressure. It is a unique treatment modality that aims to address the issue of patient compliance by offering convenient dosing schedules due to the long-lasting effect induced by vaccination.] |
|
Vapitadine
|
DB05738 |
[Vapitadine is an antihistamine that Barrier Therapeutics is developing as a treatment for allergic reactions of the skin, such as those associated with hives and for the itch associated with atopic dermatitis. An advantage of vapitadine over other antihistamines may be the absence of the sedation, even at high doses.] |
|
3-(Phosphonomethyl)Pyridine-2-Carboxylic Acid
|
DB04406 |
|
|
4-[4-(4-Methyl-2-Methylamino-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol
|
DB04407 |
|
|
Varespladib methyl
|
DB05737 |
[Varespladib methyl has been investigated for the treatment of Acute Coronary Syndrome. Studies showed that Varespladib methyl treatment resulted in significant positive changes on lipoproteins and inflammation.] |
|
MIV-701
|
DB05736 |
[MIV-701 is a selective, potent inhibitor of the protease Cathepsin K. It is developed for the treatment of osteoporosis.] |
|
Allosamizoline
|
DB04404 |
|
